New Stock News | Libang Medicine has submitted an application to the Hong Kong Stock Exchange. Its core product AP301 has completed Phase III clinical trials in China.

According to the disclosure on October 31st by the Hong Kong Stock Exchange, Livzon Pharmaceutical (Jiangsu) Co., Ltd. (referred to as Livzon Pharmaceutical) submitted its listing application to the main board of the Hong Kong Stock Exchange, with Jefferies, BofA Securities, and HTSC as joint sponsors. The prospectus shows that Livzon Pharmaceutical is a globally leading biopharmaceutical company focused on the field of kidney disease. According to the information from Zho Shi consulting, the company has the most comprehensive innovative product portfolio for kidney diseases, with the broadest coverage of indications. The CKD market is huge, worth billions of dollars, with huge growth potential. Livzon Pharmaceutical has built a vertically integrated platform covering research and development, production, and commercialization. Livzon Pharmaceutical started in the field of hyperphosphatemia and expanded into the entire field of kidney disease. By providing innovative therapies for kidney diseases, the company not only helps improve current treatment standards but also addresses the unmet medical needs of patients whose lives have been affected by kidney disease. The company has implemented a pipeline strategy focusing on kidney diseases, promoting therapies with high potential for clinical and commercial success, as well as revolutionary therapies to ensure maximum clinical value and commercial return. As of October 27, 2025, Livzon Pharmaceutical's product portfolio includes 7 candidate products (3 in clinical stages) and one commercialized product. The company's core product AP301 is a potential hyperphosphatemia binder with BIC indications for treating hyperphosphatemia. Hyperphosphatemia is one of the most common complications of chronic kidney disease, with a significant unmet medical need. AP301 has completed Phase III clinical trials in China, is expected to submit a new drug application soon, and is currently conducting global Phase III pivotal multicenter clinical trials in the US and China. In addition, AP306 is a potential FIC phosphate transporter inhibitor for treating hyperphosphatemia, which has been designated as a breakthrough therapy by the Chinese National Medical Products Administration. AP303 is a potential FIC disease-modifying product for delaying or stopping the progression of CKD, and has been granted orphan drug designation by the FDA for autosomal dominant polycystic kidney disease. AP308 is a potential global FIC recombinant immunoglobulin A protease, aimed at achieving functional cure for IgA nephropathy. The company's commercialized product Mircera is a long-acting erythropoiesis-stimulating agent approved for the treatment of anemia associated with CKD. According to the information from Zho Shi consulting, as of October 27, 2025, there are only two clinical-stage investigational molecules for hyperphosphatemia being tested globally, namely AP301 and AP306 developed by the company. Among them, AP301 has made more progress, completing the Phase III clinical trials in China and advancing the global Phase III clinical trials. In addition,...